Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Acute Sensorineural Hearing Loss Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Acute Sensorineural Hearing Loss Overview | 7 | 1 |
| Acute Sensorineural Hearing Loss Therapeutics under Development by Companies | 8 | 1 |
| Acute Sensorineural Hearing Loss Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Acute Sensorineural Hearing Loss Products under Development by Companies | 12 | 1 |
| Acute Sensorineural Hearing Loss Companies Involved in Therapeutics Development | 13 | 5 |
| Nordmark Arzneimittel GmbH &Co. KG | 13 | 1 |
| Orbis Biosciences Inc | 14 | 1 |
| Otologic Pharmaceutics, Inc. | 15 | 1 |
| Pragma Therapeutics | 16 | 1 |
| Xigen SA | 17 | 1 |
| Acute Sensorineural Hearing Loss Therapeutics Assessment | 18 | 10 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Combination Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 14 |
| (acetylcysteine + disufenton sodium) Drug Profile | 28 | 1 |
| ancrod Drug Profile | 29 | 2 |
| betamethasone valerate ER Drug Profile | 31 | 1 |
| OR-102 Drug Profile | 32 | 1 |
| Otopotin Drug Profile | 33 | 1 |
| Otostem Drug Profile | 34 | 1 |
| Small Molecules for Sensorineural Hearing Loss Drug Profile | 35 | 1 |
| Small Molecules to Agonize mGlu7 for Acute Sensorineural Hearing Loss Drug Profile | 36 | 1 |
| Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss Drug Profile | 37 | 1 |
| XG-102 Drug Profile | 38 | 4 |
| Acute Sensorineural Hearing Loss Dormant Projects | 42 | 1 |
| Acute Sensorineural Hearing Loss Product Development Milestones | 43 | 4 |
| Featured News &Press Releases | 43 | 1 |
| Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness | 43 | 1 |
| Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss | 43 | 1 |
| Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery | 44 | 1 |
| May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111 | 44 | 1 |
| Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders | 45 | 1 |
| Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss | 46 | 1 |
| Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |